RELEASE MSS4
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Dronabinol
Cannabinoid CB1 receptor agonist
What it measured
Main measures
Efficacy Endpoints:
Other measures (1)
Secondary endpoint:
Who could take part
MS (type not specified)
Inclusion: 1. Patient is male or female, aged 18 years or above. Exclusion: The patient may not enter the trial if ANY of the following apply:
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To establish the efficacy of nabiximols relative to placebo on spasm frequency in MS patients with spasticity.
Loading reviews and guidelines…
Related trials
- ICE Trial
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Trea…
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ICE
Phase 4 · Recruiting
Still running
- DRI_2020/03
Phase 3 · Not yet recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of…
Phase 2 · Recruiting
Still running
History
Started
Nov 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error